VERAXA Biotech (NASDAQ: VRXA) has announced a significant expansion of its intellectual property portfolio, filing new patent applications in the first half of 2026 to protect its next-generation BiTAC-TCE and BiTAC-ADC technology platforms and related therapeutic programs. The company, which focuses on developing innovative antibody-based cancer therapies, reported that previously granted patents have cleared the opposition period, bringing its total portfolio to more than 50 granted owned or exclusively licensed patents across 14 countries and 26 patent families. With the pending approval of the latest filings, VERAXA expects its core technologies to be protected through at least 2047.
The BiTAC platform is designed to improve the selectivity and safety of cancer therapies by activating treatments only when multiple tumor-associated targets are present, potentially reducing off-target effects. VERAXA also highlighted proprietary click chemistry, conjugation, linker and payload technologies intended to enhance the safety, efficacy and manufacturability of its antibody-drug conjugate (ADC) and T-cell engager pipelines. These advances reinforce the company's long-term strategy to develop next-generation oncology therapeutics.
The full press release is available at https://ibn.fm/BqhFS. VERAXA Biotech AG is building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs and other innovative formats. Powered by transformative technologies and guided by rigorous quality-by-design principles, the company is rapidly advancing its pipeline of ADCs and proprietary BiTAC formats into clinical development. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research.
BiTAC(R) is a registered trademark of VERAXA Biotech GmbH. For the latest news and updates relating to VRXA, visit the company's newsroom at https://ibn.fm/VRXA. This announcement underscores VERAXA's commitment to securing its intellectual property as it progresses its pipeline toward clinical development. The expanded patent coverage provides a competitive moat for its innovative platforms, which aim to address limitations in current cancer therapies by enhancing tumor specificity and reducing systemic toxicity. As the company moves forward, these patents could play a crucial role in attracting partnerships and investment, ultimately accelerating the delivery of safer, more effective treatments to patients.
